3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
145
Gynecologic
10
Thoracic
9
Gastrointestinal
7
Genitourinary
4
Head & Neck
3
Dermatologic
2
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Classical hematology
1
Conditions
Retinoblastoma
26
Advanced Solid Tumors
18
Mesothelioma
16
Mesothelioma, Malignant
15
Unspecified Adult Solid Tumor, Protocol Specific
13
Solid Tumors
9
Advanced Solid Tumor
6
Neuroblastoma
4
Unspecified Childhood Solid Tumor, Protocol Specific
3
Solid Tumor
3
Sarcoma
3
Retinal Neoplasms
3
Ovarian Neoplasms
3
Neoplasms
3
Medulloblastoma
3
Central Nervous System Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Wilms Tumor
2
Testicular Neoplasms
2
Solid Tumor, Adult
2
Rhabdoid Tumor
2
Relapsed Pediatric Solid Tumor
2
Osteosarcoma
2
Optic Nerve Glioma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Lymphoma
2
Choroid Plexus Neoplasms
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Astrocytoma
2
Interventions
pembrolizumab
6
Nivolumab
3
budigalimab
2
Paclitaxel
2
Ipilimumab
2
Docetaxel
2
venetoclax
1
tislelizumab
1
talazoparib
1
spartalizumab
1
rovalpituzumab tesirine
1
regorafenib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine
1
epacadostat
1
durvalumab
1
cabozantinib
1
Platinum
1
Levoleucovorin
1
Leucovorin
1
Interleukin-2
1
IPI-549
1
Gemcitabine
1
Fluorodeoxyglucose F18
1
Everolimus
1
Cyclophosphamide
1
Clinical Trials, Phase II as Topic
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Carboplatin
×
Other solid neoplasm
×
Clear all
NCT05579366
2026-05-26
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled